Tr1X
CA - San DiegoBiotechnology
Focus: Tr1X is a San Diego-based public biotech focused on regulatory T cell-based immunotherapies for autoimmune and inflammatory diseases. The company is in early-stage clinical development with a differentiated cell therapy approach.
Profile data last refreshed 2h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Tr1X?
AI assessmentTr1X is a bet on transformative cell therapy science, but only suitable for risk-tolerant candidates aligned with long development timelines and early-stage biotech uncertainty.
Why Work Here
- Pioneer cutting-edge Treg cell therapy platform with Phase 1/2 programs in high-unmet-need indications (Crohn's, PPMS, GvHD).
- Public company status provides liquidity, institutional credibility, and potential for equity upside as pipeline advances.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
TRX103
Hematologic MalignancyClinical Trials (1)
NCT06462365Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1Help build intelligence for Tr1X
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.